Trial Profile
A DOUBLE BLIND, RANDOMIZED, CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF SYNTHETIC SURFACTANT (CHF 5633) IN COMPARISON TO PORCINE SURFACTANT (PORACTANT ALFA, CUROSURF) IN THE TREATMENT OF PRETERM NEONATES WITH RESPIRATORY DISTRESS SYNDROME
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs Elifactant (Primary) ; Poractant alfa
- Indications Neonatal respiratory distress syndrome
- Focus Therapeutic Use
- Sponsors Chiesi Farmaceutici
- 14 Jun 2020 Primary endpoint (Reduced oxygen requirement and ventilatory support) has not been met as per results published in the Journal of Pediatrics
- 14 Jun 2020 Results published in the Journal of Pediatrics
- 05 Jul 2018 Status changed from recruiting to completed.